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A novel and sensitive assay for phospholipase D (PLD) that measures the incorporation of high specific activity PH]butan-l-01 into PH]phosphatid- 
ylbutanol has been developed. The assay has been used to measure PLD activation in human neutrophils and platelets. Both the chemotactic peptide 
fMet-Leu-Phe and opsonised-zymosan stimulated PLD in the human neutrophil. In the platelet, PLD was stimulated by thrombin and collagen 
but responses were small and only occurred at high agonist concentrations. This assay has a number of advantages over existing techniques and 
should be valuable for investigating PLD activation in a variety of isolated cells and possibly intact tissues. 
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1. INTRODUCTION 
Evidence is rapidly accumulating to indicate that 
phospholipase D (PLD) has an important role in 
receptor-effector coupling [l-3]. PLD hydrolyses 
phospholipids to yield the free polar headgroup and 
phosphatidic acid. Phosphatidic acid may have a se- 
cond messenger role [4], but such a role is more clearly 
recognized for diacylglycerol generated from 
phosphatidic acid by phosphatidate phosphohydrolase 
[5,6]. A unique feature of PLD is the ability to catalyse 
the transphosphatidylation of phospholipids. In this 
reaction the phosphatidyl moiety is transferred to a 
primary alcohol to produce the corresponding 
phosphatidylalcohol [7,8]. The formation of 
phosphatidylalcohol is therefore a useful measure of 
PLD activity in stimulated cells. 
have cytotoxic effects. Further, existing methods only 
measure PLD-dependent hydrolysis of those phos- 
pholipid pools that can be adequately radiolabelled. 
Thus, we have developed an alternative procedure that 
measures the PLD-catalysed transfer of high specific 
activity [3H]butan-l-ol into phosphatidylbutanol 
(PBut). This technique has two advantages: it uses a 
much lower concentration of alcohol (16 ,uM) and does 
not require cellular phospholipids to be prelabelled. 
Thus, it should be applicable to many cell types. 
Here we report the characterisation of this method 
using the human neutrophil and its use to investigate 
receptor-linked activation of PLD in the human 
platelet. 
2. MATERIALS AND METHODS 
The methods currently used to measure 
transphosphatidylation require cellular phospholipids 
to be prelabelled and cells to be stimulated in the 
presence of high concentrations (lo-200 mM) of 
aliphatic alcohols; radiolabelled phosphatidylalcohols 
are then separated by thin-layer chromatography 
(TLC). This approach has enabled PLD activity to be 
demonstrated in human neutrophils, NG108-15 cells, 
NIH-3T3 fibroblasts, hepatocytes and human platelets 
[g-14]. The major disadvantages of these techniques 
are that the high concentrations of alcohols required to 
obtain measurable levels of phosphatidylalcohol may 
2.1. Materials 
Radiochemicals, purchased from Amersham International (Bucks, 
UK), were [3H]butan-l-ol (12 CVmmol) and 1-stearoyl-2-[“‘Cl- 
arachidonyl phosphatidylcholine (56 mCi/mmol). Other reagents 
were from Sigma (Poole, UK) except collagen which was from 
Hormon-Chemie (Munich, FRG). Organic solvents were of analar 
grade from BDH (Poole, UK). 
2.2. Celi incubation 
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Human peripheral blood neutrophils were purified as described in 
[15] and suspended in 30 mM Hepes-buffered Hanks balanced salt 
solution, pH 7.2 (HBH). Cells (2 x lO’/ml) were pre-incubated with 
100 yCi [3H]butan-l-ol together with 5 /tM cytochalasin B, where re- 
quired, for 5 min at 37°C before the addition of agonist. fMet-Leu- 
Phe was dissolved in dimethylsulphoxide (DMSO) such that the final 
DMSO concentration did not exceed 0.2% (v/v), and opsonised- 
zymosan was suspended in HBH. Final incubation volume was 
0.5 ml. 
Washed human platelets were prepared according to [16] and 
suspended in 5 mM Hepes-buffered, calcium-free, Tyrodes solution, 
pH 7.4 (HBT). Platelets (log/ml) were incubated as described above 
except that 200 PCi [3H]butan-l-ol was used and CaClz was adjusted 
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to 1 mM. Platelet stimulants were each dissolved in HBT containing 
2 mg/ml bovine serum albumin. 
2.3. Extractions and TLC 
10000 
Reactions were terminated by adding 1.5 ml chloroform/methanol 
(1: 2, v/v), lipids extracted as described by Bligh and Dyer [17] and 
chloroform layers evaporated to dryness in streams of nitrogen. Dry 
lipid extracts were dissolved in 1 ml chloroform and washed 3 times 
with 2 ml of theoretical upper phase (upper phase of chloroform/ 
methanol/I M NaCl/HzO (2 : 2 : 1: 1, v/v)). Radiolabelled products 
were separated by TLC in a solvent system comprising the organic 
phase of 2,2,4_trimethylpentane/ethyl acetate/acetic acid/Hz0 
(5:11:2:lOv/v). 
2.4. Lipid phosphorus assay 0 
Phosphorus in lipid extracts of cell samples was determined by the 
method of Bartlett 1181. 
3. RESULTS 
Human neutrophils treated with fMet-Leu-Phe in- 
corporated [3H]butan-l-ol into a product that was 
chromatographically identical to PBut (Fig. lA, B). 
Early ex~~ments demonstrated the presence of a 
radiolabelled material that comigrated with PBut in 
control preparations. Additional studies revealed that 
this material was a minor contaminant of the high 
specific activity [3H]butan-l-ol which was readily 
removed from the lipid extract by washing the lower 
chloroform layer with theoretical upper phase [17]. Us- 
ing this washing technique we were able to measure the 
stimulated incorporation of ~3H]but~-l-ol into 
r3H]PBut by jet-Leu-Phe-stimulated human neutro- 
phils (Fig. 1A). The identity of a “C-labelled PBut 
standard, generated by incubating cabbage phos- 
pholipase D with l-stearoyl-2-[14CJarachidonyl-phos- 
phatidylcholine and butanol, was confirmed by 
demonstrating that [‘Hlbutan-l-01 was incorporated 
into a dual-labels product that was chromatographi- 
tally identical to PBut (Fig. 1B). High specific activity 
f3H]butan-l-01 was incorporated into two other 
products that were more polar than PBut; one remain- 
ed at the origin of the chromatogram (Rf = 0.03) and 
the other ran close to the PBut standard (Rf = 0.30). 
The formation of these products was neutrophil- 
dependent and production of the more polar material 
was increased by fMet-Leu-Phe treatment (Fig. 1A). A 
third broad peak of radioactivity (Rf = O&-0.9), pre- 
sent in the absence of cells, was judged to be a 
[3H]butan-l-ol contaminant that was not removed by 
the washing procedure (Fig. 1A). 
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Fig. 1. Incorporation of [3H]butan-l-ol into [“HIPBut by fMet-Leu- 
Phe-stimulated human neutrophils. Neutrophils pretreated with 
cytochalasin B were incubated with 1 pM fMet-Leu-Phe (0) or 
vehicle (0) for 5 min at 37°C in the presence of [3H]butan-l-ol as 
described in section 2. 1 cm bands were scraped from the 
c~ornato~~ and radioa~ivity quantified by liquid ScintilIation 
spectrometry. A TLC profile generated in the absence of cells is also 
shown (+). (B) Shows the TLC profile of a PBut standard prepared 
by incubating 1-stearoyl-2-I”C]arachidonyl phosphatidylcholine 
with cabbage PLD in the presence of [3H]butan-l-ol (m , r4C dpm; 
fMet-Leu-Phe stimulated the formation of [3H]PBut 
which was rapid in onset, peaked by 1 min and sustain- 
ed for 5 min (Fig. 2). The response was concentration- 
dependent with a h~f-m~imal (ED& value of 71 It 
22 nM (Fig. 3). 
Opsonised-zymosan also stimulated 13H]PBut 
generation in the human neutrophil, the magnitude of 
the response was similar to that observed for fMet-Leu- 
Fig. 2. Time comse of fMet-Leu-Phe and opsonised-zymosan- 
stimulated [‘HIPBut formation in human neutrophils. Neutrophils 
were stimulated with 0.1 FM fMet-Leu-Phe (0) or 4 mg/ml 
opsonis~-z~osan (A) in the presence of [3H]but~-l-ol for the 
indicated times as described in section 2. Data are the mean f SE for 
3 separate xperiments using cells from different donors. Basal values 
were 5140 + 1014 dpm and did not change during the 30 min 
88 
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Fig. 3. Dose-response curve for fMet-Leu-Phe-stimulated [‘HIPBut 
formation in human neutrophils. Cytochalasin B-treated neutrophils 
were incubated with fMet-Leu-Phe in the presence of 100&i 
[‘Hlbutan-l-01 for 5 min at 37°C. Lipids were extracted and 
separated by TLC as described in section 2. Data are the mean + SE 
from 3 different experiments using cells from different donors. The 
maximum response for [3H]PBut formation measured using 10 ,uM 
fMet-Leu-Phe was 24403 f 15597 dpm (mean f SE for 3 
experiments). 
Phe (0.1 PM) but the rate of formation was much 
slower (Fig. 2). 
Incubation of human platelets with high specific ac- 
tivity [3H]butan-l-ol produced labelled products hav- 
ing a TLC profile similar to that obtained from 
neutrophils. Addition of thrombin stimulated forma- 
tion of a tritiated product that was chromatographical- 
ly identical to the [14C]PBut standard (results not 
shown). In order to obtain significant amounts of this 
product, the platelet density needed to be 109/ml and 
the amount of [3H]butan-l-ol had to be increased to 
200 &i/assay. Under these conditions thrombin con- 
centrations of at least 0.5 U/ml were required to obtain 
significant increases in [3H]PBut (Fig. 4). The effects 
of other stimulatory agonists on [3H]PBut formation in 
human platelets are also shown in Fig. 4. Collagen 
1 
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Fig. 4. Formation of [3H]PBut in human platelets stimulated by 
thrombin, U46619, collagen, ADP, adrenaline and PAF. Platelets 
were treated with the appropriate stimulus for 5 min at 37°C in the 
presence of [3H]butan-l-ol and the [‘HIPBut formed was separated 
by TLC as described in section 2. Data are the means + SE from 3-4 
separate experiments using platelets from different donors. Mean 
basal values were 3732 + 861 dpm. 
Table I 
PLD levels in neutrophils and platelets 
Tissue 
Neutrophils 
Lipid 
phosphorus 
kg) 
PBut 
formed 
(pg) 
pg PBut formed 
per fig lipid 
phosphorus 
(1 x 10’ cells) 
Platelets 
1.3 f 0.3 734 + 469 549 
(5 x lo8 cells) 12.5 f 3.1 135 + 27 11 
Human neutrophils were stimulated with 1 X lo-’ M fMet-Leu-Phe 
in the presence of [‘Hlbutan-l-01 (12 Ci/mmol) and platelets 
incubated with 1 U/ml thrombin plus [‘Hlbutan-l-01 as described in 
section 2. Results are the mean + SE from 3 separate xperiments 
caused a small but significant increase in [3H]PBut, but 
ADP, the thromboxane mimetic U46619, adrenaline 
and platelet-activating factor (PAF) did not significant- 
ly increase [3H]PBut above resting levels, even at high 
concentrations. 
In order to compare levels of PLD in neutrophils and 
platelets, the amounts of PBut formed in the assay were 
expressed in terms of the total lipid phosphorus present 
in each tissue (Table I). Measurement of PLD in 
platelets required larger amounts of tissue than in 
neutrophils but platelets produced much less PBut, 
even under conditions where PLD activation was max- 
imal (Figs. 3, 4). When PBut formation is expressed as 
a function of the total lipid phosphorus it is clear that 
the platelet exhibits only 2% of the PLD activity of the 
neutrophil. 
4. DISCUSSION 
Measuring the formation of phosphatidylalcohols af- 
fords a simple and convenient method for monitoring 
PLD activation in cells. In this study the incorporation 
of high specific activity [3H]butan-1-ol into [3H]PBut 
has been used to quantify PLD activity in the human 
neutrophil and platelet. Neutrophils and platelets con- 
vert [3H]butan-l-ol into at least 3 different products 
which can be successfully separated by TLC. 
The use of [3H]butan-l-ol to monitor PLD activation 
has a number of advantages over existing methods. 
Firstly, prelabelling of phospholipid pools with 
radiolabelled precursors is avoided. This is particularly 
important when the precursor may be converted to a 
biologically active product as with, for example, I-O- 
octadecyl-2-lysophosphatidylcholine (lyso-PAF) or 
arachidonic acid. Problems concerning labelling to 
isotopic equilibrium are eliminated and the formation 
of PBut from all phospholipid substrates can be 
measured, not just those pools that are radiolabelled 
with a suitable precursor. Secondly, the high specific 
activity of the [3H]butan-l-ol ensures that only very 
89 
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low concentrations need to be used; i.e. levels that are 
1000 times less than those used in existing methods. The 
advantages are 3-fold: (i) only a small percentage of the 
phospholipid substrate(s) is converted to PBut and 
hence total phospholipid metabolism through the PLD 
pathway is not substantially altered; (ii) the possibility 
of cellular toxicity from aliphatic alcohols is reduced; 
and (iii) the chemical stability of stimulants (either par- 
ticulate or soluble) is not compromised. 
The production of [3H]PBut by cytochalasin B- 
treated neutrophils stimulated with fMet-Leu-Phe con- 
firms other reports showing that a PLD activity is link- 
ed to chemotactic peptide receptors [9,10,19]. The 
ability of cytochalasin B to ‘prime’ neutrophils and 
dramatically increase both second messenger genera- 
tion and functional responsiveness i well recognised 
[20-231. The rapid but sustained generation of 
[‘HIPBut by the neutrophil supports other observa- 
tions which indicate that phosphatidylalcohols are 
metabolically stable [24]. The metabolic stability of 
PBut has allowed us to measure long-term responses in 
the neutrophil and in particular PLD activation by par- 
ticulate stimuli. Opsonised-zymosan stimulates a slow 
activation of PLD that continues for 20-30 min. Fur- 
thermore, activation by this phagocytic stimulus does 
not require cytochalasin B pretreatment and is indepen- 
dent of a ‘priming’ event. 
Unlike the neutrophil, the human platelet exhibits 
only modest PLD activity. Indeed, measurable PBut 
formation only occurs at thrombin concentrations 
greater than those required to induce aggregation and 
secretion [25]. The only other agent that was found to 
activate PLD in the platelet was collagen and, like the 
response to thrombin, transphosphatidylation was only 
observed with a concentration of collagen greater than 
that needed to stimulate functional responses [26]. 
In conclusion, the technique described in this report 
has a number of advantages over existing procedures 
and should be useful for evaluating the physiological 
significance of PLD activation in a variety of isolated 
cells and possibly intact tissues. 
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